Effects of Medium Molecular Weight Heparinyl Phenylalnine on Superoxide Dismutase Activity in Mice

Seiichi Takeda1, Takao Toda2, Kazuki Nakamura3

  • 1Research and Development Center, Fuso Pharmaceutical Industries LTD., Osaka, Japan sei-takeda@fuso-pharm.co.jp.

In Vivo (Athens, Greece)
|November 6, 2016
PubMed

Insights

Medium molecular weight heparinyl phenylalanine (MHF) and leucine (MHL) enhance radical scavenging by increasing extracellular superoxide dismutase (EC-SOD) activity without affecting blood clotting time. MHF shows potential for clinical use.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Biomedical Science

Background:

  • Heparin (HE) derivatives are investigated for their biological activities.
  • Extracellular superoxide dismutase (EC-SOD) plays a crucial role in antioxidant defense.
  • Understanding the radical scavenging properties of modified heparins is important for therapeutic development.

Purpose of the Study:

  • To evaluate the radical scavenging ability of heparin (HE), medium molecular weight heparinyl phenylalanine (MHF), and medium molecular weight heparinyl leucine (MHL) in mice.
  • To assess the impact of these compounds on extracellular superoxide dismutase (EC-SOD) activity and activated partial thromboplastin time (APTT).

Main Methods:

  • In vivo administration of HE, MHF, and MHL to mice.
  • Measurement of plasma EC-SOD activity using the Oyanagui and Sato method.
  • Monitoring of activated partial thromboplastin time (APTT) to assess anticoagulant effects.
  • Time-dependent and dose-response analyses of EC-SOD activity.

Main Results:

  • Both HE, MHF, and MHL significantly increased plasma EC-SOD activity.
  • HE administration led to a significant prolongation of APTT, indicating anticoagulant effects.
  • MHF and MHL increased EC-SOD activity without significantly altering APTT.
  • Plasma EC-SOD activity peaked at 5 minutes post-administration for all compounds, with a bell-shaped dose-response curve.

Conclusions:

  • MHF and MHL demonstrate radical scavenging ability through the enhancement of EC-SOD activity.
  • Unlike HE, MHF and MHL do not prolong APTT, suggesting a safer anticoagulant profile.
  • MHF is identified as a potential candidate for clinical applications due to its efficacy and safety profile.